SG11201402375VA - Clostridium difficile toxin-based vaccine - Google Patents

Clostridium difficile toxin-based vaccine

Info

Publication number
SG11201402375VA
SG11201402375VA SG11201402375VA SG11201402375VA SG11201402375VA SG 11201402375V A SG11201402375V A SG 11201402375VA SG 11201402375V A SG11201402375V A SG 11201402375VA SG 11201402375V A SG11201402375V A SG 11201402375VA SG 11201402375V A SG11201402375V A SG 11201402375VA
Authority
SG
Singapore
Prior art keywords
clostridium difficile
difficile toxin
based vaccine
vaccine
toxin
Prior art date
Application number
SG11201402375VA
Inventor
Maria Scarselli
Mariagrazia Pizza
Rosanna Leuzzi
Maria Arico
Manuele Martinelli
Gillian Douce
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201121149A external-priority patent/GB201121149D0/en
Priority claimed from GBGB1217321.7A external-priority patent/GB201217321D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG11201402375VA publication Critical patent/SG11201402375VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
SG11201402375VA 2011-12-08 2012-12-07 Clostridium difficile toxin-based vaccine SG11201402375VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201121149A GB201121149D0 (en) 2011-12-08 2011-12-08 Clostridium difficile toxin-based vaccine
GBGB1217321.7A GB201217321D0 (en) 2012-09-27 2012-09-27 Vaccine
PCT/IB2012/002955 WO2013084071A2 (en) 2011-12-08 2012-12-07 Clostridium difficile toxin-based vaccine

Publications (1)

Publication Number Publication Date
SG11201402375VA true SG11201402375VA (en) 2014-10-30

Family

ID=47747684

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201402375VA SG11201402375VA (en) 2011-12-08 2012-12-07 Clostridium difficile toxin-based vaccine

Country Status (15)

Country Link
US (1) US9694063B2 (en)
EP (1) EP2788022B1 (en)
JP (1) JP6084631B2 (en)
KR (1) KR20140101835A (en)
CN (1) CN103974718A (en)
AU (1) AU2012349753A1 (en)
BR (1) BR112014013876A2 (en)
CA (1) CA2858519A1 (en)
ES (1) ES2704069T3 (en)
IL (1) IL232957A0 (en)
IN (1) IN2014CN04071A (en)
MX (1) MX2014006630A (en)
RU (1) RU2014127714A (en)
SG (1) SG11201402375VA (en)
WO (1) WO2013084071A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201911993UA (en) 2011-04-22 2020-02-27 Wyeth Llc Compositions relating to a mutant clostridium difficile toxin and methods thereof
AU2013319821A1 (en) * 2012-09-19 2015-02-26 Novartis Ag Clostridium difficile polypeptides as vaccine
BR122016023101B1 (en) * 2012-10-21 2022-03-22 Pfizer Inc Polypeptide, immunogenic composition comprising it, as well as recombinant cell derived from Clostridium difficile
WO2014197651A1 (en) * 2013-06-05 2014-12-11 Tufts University Atoxic recombinant holotoxins of clostridium difficile as immunogens
KR102395498B1 (en) 2014-01-06 2022-05-09 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
US20170218031A1 (en) * 2014-06-25 2017-08-03 Glaxosmithkline Biologicals Sa Clostridium difficile immunogenic composition
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US10668140B2 (en) 2017-02-24 2020-06-02 University Of South Floirida Non-toxigenic Clostridium difficile spores for use in oral vaccination
US10555992B2 (en) 2017-05-31 2020-02-11 University Of South Florida Immunogenic proteins against clostridium difficile
US10933126B2 (en) 2018-05-03 2021-03-02 The Board Of Regents Of The University Of Oklahoma Clostridium difficile immunogenic compositions and methods of use
EP3972638A4 (en) * 2019-05-21 2023-09-13 The Regents Of The University Of California Vaccine compositions for clostridium difficile

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
AU631377B2 (en) 1988-08-25 1992-11-26 Liposome Company, Inc., The Affinity associated vaccine
DE3841091A1 (en) 1988-12-07 1990-06-13 Behringwerke Ag SYNTHETIC ANTIGENS, METHOD FOR THEIR PRODUCTION AND THEIR USE
DE68907045T2 (en) 1989-01-17 1993-12-02 Eniricerche Spa Synthetic peptides and their use as general carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines.
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
WO1991001146A1 (en) 1989-07-14 1991-02-07 Praxis Biologics, Inc. Cytokine and hormone carriers for conjugate vaccines
IT1237764B (en) 1989-11-10 1993-06-17 Eniricerche Spa SYNTHETIC PEPTIDES USEFUL AS UNIVERSAL CARRIERS FOR THE PREPARATION OF IMMUNOGENIC CONJUGATES AND THEIR USE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES.
GB2276169A (en) 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
DE69113564T2 (en) 1990-08-13 1996-05-30 American Cyanamid Co Bordetella pertussis fiber hemagglutinin as a carrier for conjugated vaccine.
IT1262896B (en) 1992-03-06 1996-07-22 CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN (HSP) AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES.
SG90042A1 (en) 1992-06-25 2002-07-23 Smithkline Beecham Biolog Vaccine composition containing adjuvants
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE366312T1 (en) 1994-10-24 2007-07-15 Ophidian Pharm Inc VACCINE AND ANTITOXINS FOR THE TREATMENT AND PREVENTION OF C. DIFFICILE DISEASES
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
DE69610106D1 (en) 1995-07-07 2000-10-05 Oravax Inc TOXINS AND TOXOIDS FROM CLOSTRIDIUM DIFFICILE AS A MUCUTH ADJUVANS
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
EP1105153A4 (en) 1996-08-28 2005-01-19 Ophidian Pharm Inc Multivalent vaccine for (clostridium botulinum) neurotoxin
DK1005368T3 (en) 1997-03-10 2010-01-04 Ottawa Hospital Res Inst Use of nucleic acids containing non-methylated CpG dinucleotide in combination with alum as adjuvants
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
AU746859B2 (en) 1997-06-20 2002-05-02 Imperial College Of Science, Technology And Medicine Immonogenic fragments of toxin a of clostridium difficile
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
ES2201551T3 (en) 1997-09-05 2004-03-16 Glaxosmithkline Biologicals S.A. WATER OIL EMULSIONS CONTAINING SAPONINS.
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
IL137809A0 (en) 1998-02-12 2001-10-31 American Cyanamid Co Pneumococcal and meningococcal vaccines formulated with interleukin-12
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
IL138000A0 (en) 1998-04-09 2001-10-31 Smithkline Beecham Biolog Adjuvant compositions
US20020009429A1 (en) * 1999-01-29 2002-01-24 Galagen, Inc. Pharmaceutical composition comprising a selected antigen and candida species antigen and methods
DE60038166T2 (en) 1999-03-19 2009-03-12 Glaxosmithkline Biologicals S.A., Rixensart VACCINE AGAINST BACTERIAL ANTIGENE
US6733760B1 (en) * 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
JP2002541808A (en) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド Recombinant toxin A protein carrier for polysaccharide conjugate vaccine
AU781175B2 (en) 1999-04-09 2005-05-12 Intercell Usa, Inc. Recombinant toxin A/toxin B vaccine against Clostridium Difficile
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
US20040049352A1 (en) * 2000-05-10 2004-03-11 Isabelle Andre Designing modulators for glycosyltransferases
EP2284181A1 (en) 2000-10-27 2011-02-16 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups A and B
US20040107461A1 (en) * 2001-03-30 2004-06-03 Padma Commuri Glucan chain length domains
DK1450856T3 (en) 2001-09-14 2010-05-31 Cytos Biotechnology Ag Packaging of Immunostimulatory CpG in Virus-Like Particles, Method and Use
EP1425040A2 (en) 2001-09-14 2004-06-09 Cytos Biotechnology AG In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
US7226597B2 (en) 2002-06-17 2007-06-05 The Board Of Regents Of The University Of Oklahoma Mutants of Clostridium difficile toxin B and methods of use
US20040235139A1 (en) * 2002-12-23 2004-11-25 Demain Arnold L. Clostridium difficile culture and toxin production methods
CA2553946C (en) 2004-02-06 2019-02-26 University Of Massachusetts Antibodies against clostridium difficile toxins and uses thereof
AU2005321974B2 (en) 2004-12-27 2011-11-17 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
US20060228369A1 (en) 2005-04-11 2006-10-12 Program For Appropriate Technology In Health Stabilization and preservation of temperature-sensitive vaccines
WO2007146139A2 (en) 2006-06-08 2007-12-21 Cornell Research Foundation, Inc. Codon-optimized dna molecules encoding the receptor binding domains of clostridium difficile toxins a and b
CA2659684A1 (en) 2006-08-02 2008-02-07 Johannes Gutenberg-Universitaet Mainz Medicament for lct poisoning
EP2167119B1 (en) * 2007-06-14 2016-08-24 The Secretary of State for Health Chemically modified peptides with improved immunogenicity
US8524444B2 (en) * 2007-06-15 2013-09-03 President And Fellows Of Harvard College Methods and compositions for detections and modulating O-glycosylation
EP2318515A4 (en) * 2008-08-06 2012-11-14 Emergent Product Dev Uk Ltd Vaccines against clostridium difficile and methods of use
JP5740714B2 (en) 2009-02-20 2015-06-24 ヘルス プロテクション エージェンシー Antibodies against Clostridium difficile toxin
EP2470664A4 (en) 2009-08-27 2013-01-16 Synaptic Res Llc A NOVEL PROTEIN DELIVERY SYSTEM TO GENERATE INDUCED PLURIPOTENT STEM (iPS) CELLS OR TISSUE-SPECIFIC CELLS
US10046040B2 (en) 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
US20120282274A1 (en) 2009-11-20 2012-11-08 Northshore University Health System Research Institute Targeting of the c-terminal segment of c.difficile toxin b for improved clinical diagnosis, prevention, and treatment
JP2013512916A (en) * 2009-12-02 2013-04-18 タフツ ユニバーシティー Clostridium difficile non-toxic recombinant holotoxin as immunogen
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
EP2553102B1 (en) 2010-03-30 2015-12-09 Pfenex Inc. High level expression of recombinant toxin proteins
ES2757675T3 (en) * 2010-04-15 2020-04-29 Progenics Pharm Inc Antibodies for the treatment of Clostridium difficile infection and disease
MX350126B (en) 2010-09-03 2017-08-28 Valneva Austria Gmbh Isolated polypeptide of the toxin a and toxin b proteins of c. difficile and uses thereof.
US8431361B2 (en) 2010-09-17 2013-04-30 Board Of Regents Of The University Of Oklahoma Bacterial cells, optimized nucleotide sequences and methods for improved expression of recombinant Clostridium difficile toxin B
GB201016742D0 (en) * 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
US8906635B2 (en) 2011-02-28 2014-12-09 Northshore University Healthsystem Methods of diagnosing Clostridium difficile infection
SG10201911993UA (en) * 2011-04-22 2020-02-27 Wyeth Llc Compositions relating to a mutant clostridium difficile toxin and methods thereof
WO2012163810A1 (en) 2011-05-27 2012-12-06 Glaxosmithkline Biologicals S.A. Immunogenic composition
AR087716A1 (en) * 2011-08-31 2014-04-09 Valent Biosciences Corp COMPOSITIONS REGULATING GROWTH OF PLANTS, METHODS OF PREPARATION AND USES OF THE SAME
AR089797A1 (en) * 2012-01-27 2014-09-17 Merck Sharp & Dohme VACCINES AGAINST CLOSTRIDUM DIFFICILE THAT INCLUDE RECOMBINANT TOXINS
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition

Also Published As

Publication number Publication date
EP2788022B1 (en) 2018-10-31
KR20140101835A (en) 2014-08-20
WO2013084071A3 (en) 2013-11-07
CN103974718A (en) 2014-08-06
MX2014006630A (en) 2014-07-09
RU2014127714A (en) 2016-01-27
IL232957A0 (en) 2014-07-31
WO2013084071A2 (en) 2013-06-13
JP6084631B2 (en) 2017-02-22
EP2788022A2 (en) 2014-10-15
BR112014013876A2 (en) 2019-09-24
IN2014CN04071A (en) 2015-10-23
ES2704069T3 (en) 2019-03-14
US9694063B2 (en) 2017-07-04
JP2015500827A (en) 2015-01-08
CA2858519A1 (en) 2013-06-13
AU2012349753A1 (en) 2014-06-19
US20150132333A1 (en) 2015-05-14

Similar Documents

Publication Publication Date Title
HK1202060A1 (en) Rna formulation for immunotherapy rna
DK3327110T3 (en) Kassette til sterilitetstest
DK2737264T3 (en) Startlogik til kølesystem
IL232957A0 (en) Clostridium difficile toxin-based vaccine
HK1199886A1 (en) Clostridium difficile antibodies
GB201016742D0 (en) Clostridium difficile antigens
HK1202805A1 (en) Clostridium difficile antigens
EP2729605A4 (en) Rna-yy1 interactions
EP2698206A4 (en) Cone-shaped crusher
IL231043A (en) Vaccine
HK1216999A1 (en) Antibodies against clostridium difficile
IL237172A0 (en) פוליפפטידים של clostridium difficile כתרכיבים
EP2698205A4 (en) Cone-shaped crusher
GB201119999D0 (en) Vaccine
EP2763699A4 (en) Vaccine
ZA201306245B (en) Combination vaccines
EP2771453A4 (en) Diatom-based vaccines
RS58794B1 (en) Rna formulation for immunotherapy
EP2770046A4 (en) Culture device
GB201120000D0 (en) Vaccine
HK1203416A1 (en) Novel clostridium difficile dna vaccine dna
GB201121149D0 (en) Clostridium difficile toxin-based vaccine
IL231661A0 (en) Clostridium difficile antibodies
DK2700058T3 (en) Drev til internt transportsystem
GB201108982D0 (en) Vaccines